Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364123 | 1.00 | CTSS (0.41) | CTSSCTSKKDM4EALDH1A1GAA | |
| SCHEMBL30558136 | 1.00 | CTSS (0.41) | CTSSCTSKKDM4EALDH1A1GAA | |
| SCHEMBL3762203 | 0.86 | CTSS (0.43) | CTSSCTSKALDH1A1AAK1TRPA1 | |
| SCHEMBL30765251 | 0.86 | CTSS (0.43) | CTSSCTSKALDH1A1AAK1TRPA1 | |
| SCHEMBL17395943 | 0.85 | CTSS (0.49) | CTSSCTSKITGA4ITGB7ACE | |
| SCHEMBL21777294 | 0.85 | CTSS (0.49) | CTSSCTSKITGA4ITGB7ACE | |
| SCHEMBL265969 | 0.85 | CTSS (0.49) | CTSSCTSKITGA4ITGB7ACE | |
| SCHEMBL23414163 | 0.84 | CTSS (0.40) | CTSSCTSKKDM4EALDH1A1GAA | |
| SCHEMBL3822263 | 0.83 | CTSS (0.43) | CTSSCTSKAAK1TRPA1ACE | |
| SCHEMBL29571131 | 0.83 | CTSS (0.43) | CTSSCTSKAAK1TRPA1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110753691-B | Compounds for therapeutic and/or prophylactic treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116693518-A | Synthesis and application of EGFR inhibitor | 江南大学 | 2023-09-05 | — | — | CN | disclosed |
| EP-3986565-B1 | NEW EGFR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20220315577-A1 | NEW EGFR INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3630754-B1 | ISOINDOLINE-ACETYLENE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2022-07-27 | — | — | EP | disclosed |
| EP-3986565-A1 | NEW EGFR INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993589-A | Novel EGFR inhibitors | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-11117890-B2 | Substituted isoindole allosteric EGFR inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020254544-A1 | NEW EGFR INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |
| EP-3749664-A1 | COMPOUNDS WHICH CAUSE DEGRADATION OF EGFR, FOR USE AGAINST CANCER | F. Hoffmann-La Roche AG (CH) | 2020-12-16 | — | — | EP | disclosed |
| EP-3630754-A1 | COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102299-A1 | COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-04-02 | — | — | US | disclosed |
| CN-110753691-A | Compound (I) | 豪夫迈·罗氏有限公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2019149922-A1 | COMPOUNDS WHICH CAUSE DEGRADATION OF EGFR, FOR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2019-08-08 | — | — | WO | disclosed |
| WO-2018220149-A1 | COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-06 | — | — | WO | disclosed |
| EP-1791837-B1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1791837-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029862-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117890-B2 | Substituted isoindole allosteric EGFR inhibitors | EGFR, ERBB2, ERBB3 | CTSS 4274/4885CTSK 3549/4885KDM4E 2855/4885 |
| US-20200102299-A1 | COMPOUNDS | EGFR, ERBB2, ERBB3 | CTSS 1132/4885CTSK 2666/4885KDM4E 2845/4885 |
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CTSS 1158/4885CTSK 1629/4885KDM4E 704/4885 |
| US-20220315577-A1 | NEW EGFR INHIBITORS | EGFR, ERBB3, ERBB2 | CTSS 1340/4885CTSK 912/4885KDM4E 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.